FibroGen Inc (NASDAQ:FGEN) Director Thomas F. Kearns, Jr. sold 18,000 shares of the firm’s stock in a transaction dated Monday, March 12th. The shares were sold at an average price of $55.00, for a total transaction of $990,000.00. Following the transaction, the director now directly owns 135,064 shares in the company, valued at approximately $7,428,520. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
FibroGen Inc (NASDAQ:FGEN) traded down $1.35 during trading hours on Tuesday, hitting $53.45. 511,319 shares of the stock traded hands, compared to its average volume of 665,576. FibroGen Inc has a one year low of $22.75 and a one year high of $63.00. The company has a debt-to-equity ratio of 0.17, a quick ratio of 9.70 and a current ratio of 9.70. The company has a market cap of $4,370.00, a price-to-earnings ratio of -30.37 and a beta of 1.76.
Several large investors have recently bought and sold shares of FGEN. Parametric Portfolio Associates LLC boosted its position in shares of FibroGen by 44.2% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 14,590 shares of the biopharmaceutical company’s stock valued at $471,000 after purchasing an additional 4,470 shares in the last quarter. Nationwide Fund Advisors boosted its position in shares of FibroGen by 9.3% during the 3rd quarter. Nationwide Fund Advisors now owns 234,753 shares of the biopharmaceutical company’s stock valued at $12,630,000 after purchasing an additional 19,954 shares in the last quarter. First Trust Advisors LP boosted its position in shares of FibroGen by 261.5% during the 3rd quarter. First Trust Advisors LP now owns 67,042 shares of the biopharmaceutical company’s stock valued at $3,607,000 after purchasing an additional 48,494 shares in the last quarter. Victory Capital Management Inc. bought a new position in shares of FibroGen during the 3rd quarter valued at about $606,000. Finally, Stevens Capital Management LP bought a new position in shares of FibroGen during the 3rd quarter valued at about $1,090,000. Institutional investors own 61.39% of the company’s stock.
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.